MDxHealth Announces Presentations on the ConfirmMDx(TM) for Prostate Cancer Test at the ASCO Genitourinary Cancers Symposium 2013 IRVINE, CA and LIEGE, BELGIUM -- (Marketwire) -- 02/13/13 -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced that the company will present results from two important studies involving its ConfirmMDx(TM) for Prostate Cancer test at the ASCO Genitourinary Cancers Symposium 2013, February 14-16, Orlando, Florida, USA. Following are details for each embargoed session (all times are in Eastern Standard Time) follow: Thursday, February 14, 2013 Abstract Title: Epigenetic Field Effects for DNA Methylation Markers Extend Over Multiple Histologically Benign Prostate Biopsy Cores Lead Author: Sandra M Gaston PhD, New England Baptist Hospital, Harvard Medical School Location: Prostate Cancer poster session: Poster 116 Time: 11:45AM Abstract Title: Multi-gene Epigenetic MSP Assay Predicts Risk for Prostate Cancer in Histopathologically Negative Biopsies Lead Author: Leander van Neste PhD, MDxHealth SA, Liege, Belgium Location: Prostate Cancer poster session: Poster 95 Time: 11:45AM About ConfirmMDx for Prostate Cancer Over 650,000 American men receive a negative prostate biopsy result each year; though approximately 25% of these men may still harbor occult prostate cancer. This well-documented risk of undetected cancer, often with clinically significant Gleason scores, leads to a high rate of repeat biopsies with over 40% of men receiving at least one repeat biopsy, and many receiving a 3rd and 4th biopsy. Today's gold standard diagnostic approach is the prostate biopsy procedure, collecting 10-12 needle core biopsy samples, however this sampling represents less than 1% of a man's prostate. ConfirmMDx for Prostate Cancer is an epigenetic assay to help urologists distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test is able to detect an epigenetic field effect or "halo" associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular "halo" around a cancer lesion can be present despite having a normal appearance under the microscope. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and helps rule in high-risk patients who may require repeat biopsies and potential treatment. About MDxHealth MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, the ConfirmMDx for Prostate Cancer test, has been shown to help distinguish patients who have a true-negative biopsy from those who may have occult cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for brain and lung cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium. For more information visit MDxHealth website at www.mdxhealth.com. This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws. NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners. ASCO ENG: http://hugin.info/137314/R/1677471/547059.pdf Contacts Dr Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70 firstname.lastname@example.org Mike Sinclair Halsin Partners UK: +44 20 7318 2955 Cell: +44 7968 022075 email@example.com Seth Lewis The Trout Group US: +1 646 378 2952 --- firstname.lastname@example.org
MDxHealth Announces Presentations on the ConfirmMDx(TM) for Prostate Cancer Test at the ASCO Genitourinary Cancers Symposium
Press spacebar to pause and continue. Press esc to stop.